Clinical Trial

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This partially randomized phase II/III trial studies how well, in combination with surgery, cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or hepatocellular carcinoma. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone.
Protocol Amendment History 63 amendments
This ClinicalTrials.gov record has been amended 63 times since 2018-05-22; most recent amendment 2026-07-15.
Status change: Recruiting → Active, Not Recruiting 2024-01-18
Status change: Not Yet Recruiting → Recruiting 2018-05-25
Trial Details
NCT Number NCT03533582
Lead Sponsor Children's Oncology Group
Collaborators: National Cancer Institute (NCI)
Conditions Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Enrollment 537 participants
Start Date 2018-05-24
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-16